August 23, 2017
Posted November 27, 2017
US Bioservices Corp. agreed to pay $13.4 million to settle charges it violated the False Claims Act and Anti-Kickback Statute by participating in a kickback scheme with Novartis Pharmaceuticals Corp. relating to the Novartis drug Exjade. Specifically, the government alleges US Bio was promised additional patient referrals and related benefits in return for refilling a higher percentage of Exjade than the two other pharmacies that also dispensed Exjade. DOJ (SDNY)
Tagged in: Anti-Kickback and Stark, FCA Federal, Pharma Fraud,